<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00979056</url>
  </required_header>
  <id_info>
    <org_study_id>Rifa1</org_study_id>
    <secondary_id>2007-003986-42</secondary_id>
    <nct_id>NCT00979056</nct_id>
  </id_info>
  <brief_title>Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin</brief_title>
  <official_title>Prospective, Randomised, Placebo Controlled, Double Blind Monocenter Trial for the Prophylactic Treatment of Diarrhoea With Rifaximin for Travellers to South- and Southeast-Asia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Philipp Zanger, MD MSc DTM</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the efficacy of the prophylactic treatment with
      rifaximin to prevent travellers diarrhoea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of the prevention of travellers diarrhea with rifaximin by measurement of frequency and consistence of the stool. Diarrhea will be defined as passage of &gt;2 unformed stools/24 hr plus one or more signs or symptoms of enteric infection.</measure>
    <time_frame>From the first day of the travel (travel period between 6 and 28 days) to 1 week after the subject's return to Germany</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Documentation of adverse effects and tolerance of prophylaxis with rifaximin.</measure>
    <time_frame>From the first day of the travel (travel period between 6 and 28 days) to 1 week after the subject's return to Germany</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of prevention of post infectious irritable bowel syndrome.</measure>
    <time_frame>From the first day of the travel (travel period between 6 and 28 days) to 6 months after the subject's return to Germany</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Diarrhoea</condition>
  <arm_group>
    <arm_group_label>Rifaximin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>400 mg per day, oral use, maximum duration 28 days</description>
    <arm_group_label>Rifaximin</arm_group_label>
    <other_name>Xifaxan</other_name>
    <other_name>Normix</other_name>
    <other_name>ATC code A07AA11</other_name>
    <other_name>Chemical Abstracts Service (CAS) 80621814</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose</intervention_name>
    <description>Coated Tablet, Oral Use</description>
    <arm_group_label>Lactose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥ 18 and &lt; 65 years

          -  Good general condition (according to history and clinical examination)

          -  Written informed consent

          -  No pregnancy

          -  No breast feeding

          -  Efficacious contraception (e.g. oral, double-barrier) during the study and 4 weeks
             after termination of the study

          -  No participation in other clinical trials 4 weeks before, during participation, and 4
             weeks after participation in this study

          -  Planned travel period between 6 and 28 days

          -  Planned travel to South- and Southeast Asia

          -  Planned time to arrival in South- or Southeast Asia ≤ 24 hours

        Exclusion Criteria:

          -  Pregnancy

          -  Breast feeding

          -  Age &lt; 18 and ≥ 65 years

          -  No written informed consent

          -  Chronic gastrointestinal disease and/ or immune insufficiency

          -  Low general condition (according to history and clinical examination)

          -  Regular medication with gastrointestinal side-effects and/or immunosuppressive
             medication

          -  Participation in other clinical trials 4 weeks before, during and 4 weeks after
             termination of the study

          -  No efficacious contraception

          -  Planned travel period &lt; 6 and &gt; 28 days

          -  Planned travel outside South- and Southeast Asia

          -  Vaccination against cholera using DUKORAL within 12 months prior to inclusion

          -  Planned time to arrival in South- or Southeast Asia &gt; 24 hours

          -  Known hypersensitivity against rifaximin or rifamycin-derivatives in general

          -  Known lactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp G. Zanger, MD MSc DTM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Tropical Medicine, University Hospital of Tübingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Tropical Medicine, University Hospital of Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Zanger P, Nurjadi D, Gabor J, Gaile M, Kremsner PG. Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2013 Nov;13(11):946-54. doi: 10.1016/S1473-3099(13)70221-4. Epub 2013 Sep 4.</citation>
    <PMID>24012319</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2009</study_first_submitted>
  <study_first_submitted_qc>September 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2009</study_first_posted>
  <last_update_submitted>November 7, 2013</last_update_submitted>
  <last_update_submitted_qc>November 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Dr. Philipp Zanger, MD MSc DTM</investigator_full_name>
    <investigator_title>Oberarzt</investigator_title>
  </responsible_party>
  <keyword>Traveller's diarrhoea</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

